Anas Younes, Senior VP, Global Head of Hematology (Early and Late Stage), Oncology R&D at AstraZeneca, shared a post on LinkedIn:
“There’s been remarkable progress made in haematology care in recent years. For example, cell therapy is transforming outcomes for some people living with certain types of blood cancer, while immunotherapy and targeted therapy combinations have improved outcomes for patients with relapsed multiple myeloma. Yet significant unmet needs remain, especially for aggressive leukaemias and high-risk lymphomas.
Our pipeline spans multiple modalities – including cell therapies, T-cell engagers, antibody drug conjugates and small molecules – each designed to uniquely address disease biology and reduce the treatment burden for patients.
To discover how my Astra Zeneca colleagues like Nina Shah MD and Bruno Medeiros are driving innovation that could potentially reshape the standards of care, I encourage you to read more in our ‘What Science Can Do’ blog.”
More posts featuring Anas Younes on OncoDaily.